Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1984-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1365-2125.1984.TB02567.XPMID 6529534PMCID PMC1463695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diazepam plasma binding in the perinatal period: Influence of nonesterified fatty acids

  2004cited by this paper
• Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

  1983cited by this paper
• Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.

  1983cited by this paper
• Altered plasma drug binding in cancer: Role of α1‐acid glycoprotein and albumin

  1982cited by this paper
• Pharmacokinetics of Drugs in Obesity

  1982cited by this paper
• Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin.

  1982cited by this paper
• Kinetics of induction of alpha 1-acid glycoprotein.

  1982cited by this paper
• Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).

  1982cited by this paper
• KINETICS OF INDUCTION OF α1‐ACID GLYCOPROTEIN *

  1982cited by this paper
• Relationship between α1‐acid glycoprotein and lidocaine disposition in myocardial infarction

  1981cited by this paper
• Thiopental kinetics in obese surgical patients

  1981cited by this paper
• A sensitive method for the determination of free fatty acids in plasma.

  1981cited by this paper
• Alterations in drug distribution and clearance due to obesity.

  1981cited by this paper
• Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.

  1981cited by this paper
• Obesity, lipids, and glucose intolerance. The Framingham Study.

  1979cited by this paper
• Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

  1978cited by this paper
• Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study.

  1977cited by this paper
• Immunochemical quantitation of antigens by single radial immunodiffusion.

  1965cited by this paper
• Indices of Adiposity

  1962cited by this paper
• Determination of serum proteins by means of the biuret reaction.

  1949cited by this paper

• Determination of Serum Alpha-1-Acid Glycoprotein Concentration and the Influence of Physiological and Gynecological Factors in Women Attending in Tertiary-Care Center in Mexico: A Pilot Study

  2025cites this paper
• The Role of Orosomucoid in Glucose and lipid Metabolism and Metabolic Diseases.

  2025cites this paper
• Impact of Obesity on Hepatic Drug Clearance: What are the Influential Variables?

  2024cites this paper
• Updated antimicrobial dosing recommendations for obese patients

  2024cites this paper
• The Influence of High Body Mass Index (BMI > 35 kg/m2) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation

  2024cites this paper
• The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine

  2024cites this paper
• A comparative evaluation of propranolol pharmacokinetics in obese versus ideal weight individuals: A blueprint towards a personalised medicine.

  2023cites this paper
• Effectiveness and Safety of Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients With Extreme Obesity.

  2023cites this paper
• Pharmacokinetics of obese adults: Not only an increase in weight.

  2023cites this paper
• Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models

  2022cites this paper
• Review and evaluation of vancomycin dosing guidelines for obese individuals

  2022cites this paper
• Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations

  2022cites this paper
• Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling

  2021cites this paper
• Dosage adjustment in obese children, even for common drugs, is largely unclear and a treat-to-effect approach may work best

  2020cites this paper
• Diagnostic prediction model development using data from dried blood spot proteomics and a digital mental health assessment to identify major depressive disorder among individuals presenting with low mood.

  2020cites this paper
• Effect of periodontal therapy on adipokine biomarkers in overweight.

  2020cites this paper
• Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children

  2019cites this paper
• Product Labeling of Drugs Commonly Administered to Children and Adults with Obesity.

  2019cites this paper
• Obesity and chemotherapy administration: between empiric and mathematic method review

  2019cites this paper
• Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects

  2018cites this paper
• Higher chlorzoxazone clearance in obese children compared with nonobese peers

  2018cites this paper
• Dosing in Obese Critically Ill Patients

  2018cites this paper
• Parameterization of In Silico Oral Disposition Models: Focus on Pediatrics

  2017cites this paper
• Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes

  2017cites this paper
• Challenges to Safe and Effective Pain Management in Patients With Super Obesity: Case Report and Literature Review.

  2017cites this paper
• Effects of Food and Nutritional Status of Animals on Antimicrobial Drug Disposition

  2017cites this paper
• Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers

  2016cites this paper
• Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.

  2016cites this paper
• Optimization of antibiotic therapy in the obese, critically ill patient

  2015cites this paper
• Inflammation profile in overweight/obese adolescents in Europe: an analysis in relation to iron status

  2014cites this paper
• Quantitative Proteomics for Cardiac Biomarker Discovery Using Isoproterenol-Treated Nonhuman Primates

  2014cites this paper
• Does obesity prolong anesthesia in children undergoing common ENT surgery?

  2014cites this paper
• Proteomic analysis allows for early detection of potential markers of metabolic impairment in very young obese children

  2014cites this paper
• Physiologically-based pharmacokinetic modelling and simulation of oral drug bioavailability: Focus on bariatric surgery patients and mechanism-based inhibition of gut wall metabolism

  2014cites this paper
• Obesity-related physiological changes and their pharmacokinetic consequences

  2013cites this paper
• A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution

  2012cites this paper
• Orosomucoid serum concentrations and fat depot-specific mRNA and protein expression in humans

  2012cites this paper
• Maternal obesity alters feto-placental cytochrome P4501A1 activity.

  2012cites this paper
• Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib

  2012cites this paper
• The effects of obesity on drug pharmacokinetics in humans

  2011cites this paper
• Simulation of Population Variability in Pharmacokinetics

  2011cites this paper
• Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients

  2011cites this paper
• Dose optimization and body size

  2011cites this paper
• Methadone: a review of drug-drug and pathophysiological interactions

  2011cites this paper
• Dosing dilemmas in obese children

  2010cites this paper
• Adjustment of dosing of antimicrobial agents for bodyweight in adults.

  2010cites this paper
• Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  2010cites this paper
• Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

  2009cites this paper
• 2D-DIGE Proteomic Approaches Reveal Urine Candidate Biomarkers in Pediatric Obstructive Sleep Apnea

  2009cites this paper
• Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea.

  2009cites this paper
• Influence of Overweight and Obesity on Medication

  2009cites this paper
• Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD

  2008cites this paper
• Scientific and Regulatory Considerations for Studies in Special Populations

  2004cites this paper
• Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women

  2004cites this paper
• Influence of Obesity on Drug Disposition and Effect

  2004cites this paper
• Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.

  2004cites this paper
• Gastro‐oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations

  2002cites this paper
• HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡

  2001cites this paper
• Effects of obesity on pharmacokinetics implications for drug therapy.

  2000cites this paper
• Effects of Obesity on Pharmacokinetics

  2000cites this paper
• Increase of adhesion molecules, fibrinogen, type‐1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement

  2000cites this paper
• Pharmacokinetic considerations in obesity.

  1999cites this paper
• Risk of gallstone disease is associated with serum level of alpha-1-acid glycoprotein.

  1999cites this paper
• The obese patient in the ICU.

  1998cites this paper
• Antimicrobial dosing in obese patients.

  1997cites this paper
• Drug Distribution in Obesity and following Bariatric Surgery: A Literature Review

  1996cites this paper
• Measurement and Analysis of Unbound Drug Concentrations

  1996cites this paper
• In Vitro Plasma Protein Binding of Neuromuscular Blocking Agents in Different Subpopulations of Patients

  1995cites this paper
• Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men.

  1995cites this paper
• Clinical Pharmacokinetics of Drugs in Obesity

  1993cites this paper
• Serum alpha‐1 acid glycoprotein levels in patients with idiopathic peripheral retinal vasculitis (Eales' disease)

  1992cites this paper
• Ex Vivo Protein Binding of Clindamycin in Sera With Normal and Elevated α1‐Acid Glycoprotein Concentrations

  1992cites this paper
• Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women.

  1991cites this paper
• Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

  1990cites this paper
• Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.

  1990cites this paper
• Comparison of Propranolol and Sotalol Pharmacokinetics in Obese Subjects

  1990cites this paper
• Disease-Induced Variations in Plasma Protein Levels

  1990cites this paper
• Binding of d‐methadone, 1‐methadone, and dl‐methadone to proteins in plasma of healthy volunteers: Role of the variants of α1‐acid glycoprotein

  1990cites this paper
• Pharmacokinetic characteristics of the obese overfed rat.

  1989cites this paper
• Phenytoin dosing in obese patients: two case reports.

  1988cites this paper
• Verapamil pharmacodynamics and disposition in obese hypertensive patients.

  1988cites this paper
• Phenytoin Dosing in Obese Patients: Two Case Reports

  1988cites this paper
• Drug binding to human alpha-1-acid glycoprotein in health and disease.

  1988cites this paper
• DRUG PHARMACOKINETICS IN THE OBESE

  1988cites this paper
• DRUG PHARMACOKINETICS IN THE OBESE *

  1988cites this paper
• Comparative Pharmacokinetics of Intravenous Propranolol in Obese and Normal Volunteers

  1987cites this paper
• Clinical Pharmacokinetics and Endocrine Disorders

  1987cites this paper
• Disopyramide pharmacokinetics and metabolism: effect of inducers.

  1987cites this paper
• Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein.

  1986cites this paper
• Free Drug Concentration Monitoring in Clinical Practice

  1986cites this paper
• Drug Disposition in Obese Humans

  1986cites this paper
• Free drug concentration monitoring in clinical practice. Rationale and current status.

  1986cites this paper
• Altered drug-serum protein binding in the genetically obese Zucker rat.

  1985cites this paper
• critical care The Obese Patient in the ICU *

  year unknowncites this paper